NCT01656200

A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Indian Institute of Science · Other Government
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Japanese encephalitis (JE) live attenuated vaccine SA14-14-2 has been in use for more more than 20 years in Asia. JE vaccine SA14-14-2 is licensed in India and has been widely used since 2006. JE vaccines give protection by generating a neutralizing antibody response, but both naturally exposed persons and patients with JE also have T cell responses. Whether JE vaccine SA14-14-2 elicits T cell responses is unknown. This study tests the hypothesis that T cell responses are generated in response to JE SA14-14-2 vaccination. The aim of this study is to characterize T cell responses to JE vaccine SA14-14-2 in healthy people, and to investigate differences in T cell responses between natural exposure, vaccination and disease.

Conditions

• Japanese Encephalitis
• Japanese Encephalitis Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	Live attenuated Japanese encephalitis vaccine SA14-14-2	Live attenuated Japanese encephalitis vaccine SA14-14-2

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-10-01
• Completion: 2014-03-01
• First posted: 2012-08-02
• Last updated: 2019-04-26
• Results posted: 2019-04-26

Locations

2 sites across 1 country: India